Key result
Brugada syndrome genetics identify over 40 associated genes, predominantly SCN5A, to guide emerging gene-specific therapies.
Why the study?
A comprehensive view of gene variants associated with Brugada syndrome pathogenicity and their pathophysiological mechanisms is still lacking despite advances in molecular genetics.
This review summarizes the genetic mechanisms underlying Brugada syndrome and highlights the rapid evolution of gene-specific therapies.
Gene-specific Brugada therapies remain investigational; leaves open the need for clinical validation of identified targets.
Brugada syndrome is an inherited disease closely associated with genetic mutations, resulting in ventricular fibrillation and sudden cardiac death. To date, more than 40 genes have been identified to participate in the etiology of this devastating myocardial pathology, among which SCN5A is the predominant cause. Although considerable advances have been made in the molecular genetics of Brugada syndrome over the past decades, a comprehensive view of gene variants associated with Brugada syndrome pathogenicity and their pathophysiological mechanisms is still lacking. Recent studies have reanalyzed and reevaluated relevant genes and further elaborated genetic mechanisms underneath Brugada syndrome. Currently, gene-specific therapies based on culprit pathogenic genes are rapidly evolving, thus offering prospects for future research.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2023) conducted a review in Brugada syndrome. Recent advances in the molecular genetics of Brugada syndrome have identified over 40 associated genes, predominantly SCN5A, paving the way for rapidly evolving gene-specific therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: